SG11201805092WA - Cortistatin analogs and uses thereof - Google Patents
Cortistatin analogs and uses thereofInfo
- Publication number
- SG11201805092WA SG11201805092WA SG11201805092WA SG11201805092WA SG11201805092WA SG 11201805092W A SG11201805092W A SG 11201805092WA SG 11201805092W A SG11201805092W A SG 11201805092WA SG 11201805092W A SG11201805092W A SG 11201805092WA SG 11201805092W A SG11201805092W A SG 11201805092WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- mpk
- quincy
- president
- cambridge
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization IIIMIOH0110101011111 HO 11111011101110111 011111111011110111111011011# International Bureau .. .... ..Yejd (10) International Publication Number (43) International Publication Date ..... ...r .....1 WO 2017/112815 Al 29 June 2017(29.06.2017) WIPO I PCT (51) International Patent Classification: C07D 519/00 (2006.01) C07K 16/26 C07D 493/08 (2006.01) (21) International Application Number: (22) International Filing Date: 21 December (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/387,246 23 December 2015 (23.12.2015) 62/297,494 19 February 2016 (19.02.2016) (71) Applicant: PRESIDENT AND FELLOWS VARD COLLEGE [US/US]; 17 MA 02138 (US). (72) Inventors: SHAIR, Matthew, D.; lows of Harvard College, 17 Quincy MA (US). PELISH, Henry, Efrem; AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, PCT/US2016/068125 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 2016 (21.12.2016) RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, English ZA, ZM, ZW. English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, OF HAR- DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Quincy St, Cambridge, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). c/o President and Fel- Street, Cambridge, Declarations under Rule 4.17: c/o President and Fel- - as to applicant's entitlement to apply for and be granted a Street, Cambridge, patent (Rule 4.17(ii)) — as to the applicant's entitlement to claim the priority of the al.; Knowles Intellectu- earlier application (Rule 4.17(iii)) Center Terrace Published: indicated, for every — with international search report (Art. 21(3)) AE, AG, AL, AM, — lows of Harvard College, 17 Quincy — MA (US). = (74) Agents: BELLOWS, Brent, R. et Property LLC, 400 Perimeter al Strategies, NE, Suite 200, Atlanta, GA 30346 (US). (81) (unless otherwise Designated States = kind of national available): protection = USES THEREOF .4. vehicle .0.. F 1 mpk PO CA 0.16 mpk IP -4- B It) mpk PO = (54) Title: CORTISTATIN ANALOGS AND = = = = GI 0 = .61 32768 .. = .0 16384 . _ c 8192 . = 4096 2048 0 0 go 1024 _ c„) 512 _ 0 eD 256 .9 128 C 5 mpk PO -is. D 3nips; IV 1-1 & ir) 1 3 6 9 1.2 15 ,-1 Treatment days GC ei 11 FIG. 31 11 IN 1-1 (57) : Specific Cortistatin derivatives with advantageous properties for in vivo administration to a host, including a human, N in need thereof are provided. These novel species have advantageous pharmacokinetics, low toxicity, low to moderate hERG activ - ity, and/or other pharmacological properties which make them stand out among the class of Cortistatins as superior candidates for 0 human administration.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562387246P | 2015-12-23 | 2015-12-23 | |
US201662297494P | 2016-02-19 | 2016-02-19 | |
PCT/US2016/068125 WO2017112815A1 (en) | 2015-12-23 | 2016-12-21 | Cortistatin analogs and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201805092WA true SG11201805092WA (en) | 2018-07-30 |
Family
ID=59091204
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201805092WA SG11201805092WA (en) | 2015-12-23 | 2016-12-21 | Cortistatin analogs and uses thereof |
Country Status (17)
Country | Link |
---|---|
US (1) | US20180298024A1 (en) |
EP (1) | EP3394072A4 (en) |
JP (1) | JP2019508368A (en) |
KR (1) | KR20180095051A (en) |
CN (1) | CN108699085A (en) |
AU (1) | AU2016377678A1 (en) |
BR (1) | BR112018012647A2 (en) |
CA (1) | CA3009324A1 (en) |
CL (1) | CL2018001733A1 (en) |
CO (1) | CO2018007535A2 (en) |
EA (1) | EA201891511A1 (en) |
IL (1) | IL260123A (en) |
MX (1) | MX2018007804A (en) |
PH (1) | PH12018501351A1 (en) |
RU (1) | RU2018126984A (en) |
SG (1) | SG11201805092WA (en) |
WO (1) | WO2017112815A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2988601C (en) | 2015-07-02 | 2021-12-07 | F. Hoffmann-La Roche Ag | Bicyclic lactams and methods of use thereof |
EP3526219B1 (en) | 2016-10-17 | 2021-12-15 | F. Hoffmann-La Roche AG | Bicyclic pyridone lactams and methods of use thereof |
US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
EP3781571B1 (en) | 2018-04-20 | 2024-01-17 | F. Hoffmann-La Roche AG | N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
AU2019374142A1 (en) * | 2018-11-01 | 2021-05-27 | Syros Pharmaceuticals, Inc. | Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (CDK7) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2723689C (en) * | 2008-05-05 | 2016-07-05 | Ryan A. Shenvi | Synthesis of (+) cortistatin a and related compounds |
WO2010024930A2 (en) * | 2008-08-28 | 2010-03-04 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses therof |
US20130217014A1 (en) * | 2012-02-17 | 2013-08-22 | Genentech, Inc. | Methods of using cdk8 antagonists |
WO2014123900A1 (en) * | 2013-02-05 | 2014-08-14 | Sirenas Marine Discovery | Anti-cancer and anti-hiv compounds |
JP6494631B2 (en) * | 2013-12-24 | 2019-04-03 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Colchistatin analogues and their synthesis and use |
-
2016
- 2016-12-21 SG SG11201805092WA patent/SG11201805092WA/en unknown
- 2016-12-21 MX MX2018007804A patent/MX2018007804A/en unknown
- 2016-12-21 BR BR112018012647A patent/BR112018012647A2/en not_active Application Discontinuation
- 2016-12-21 RU RU2018126984A patent/RU2018126984A/en not_active Application Discontinuation
- 2016-12-21 AU AU2016377678A patent/AU2016377678A1/en not_active Abandoned
- 2016-12-21 CN CN201680082319.0A patent/CN108699085A/en active Pending
- 2016-12-21 JP JP2018532374A patent/JP2019508368A/en active Pending
- 2016-12-21 CA CA3009324A patent/CA3009324A1/en not_active Abandoned
- 2016-12-21 EP EP16880055.5A patent/EP3394072A4/en not_active Withdrawn
- 2016-12-21 EA EA201891511A patent/EA201891511A1/en unknown
- 2016-12-21 KR KR1020187020634A patent/KR20180095051A/en unknown
- 2016-12-21 WO PCT/US2016/068125 patent/WO2017112815A1/en active Application Filing
-
2018
- 2018-06-18 IL IL260123A patent/IL260123A/en unknown
- 2018-06-22 CL CL2018001733A patent/CL2018001733A1/en unknown
- 2018-06-22 PH PH12018501351A patent/PH12018501351A1/en unknown
- 2018-06-22 US US16/016,199 patent/US20180298024A1/en not_active Abandoned
- 2018-07-18 CO CONC2018/0007535A patent/CO2018007535A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2019508368A (en) | 2019-03-28 |
AU2016377678A1 (en) | 2018-07-12 |
CN108699085A (en) | 2018-10-23 |
US20180298024A1 (en) | 2018-10-18 |
BR112018012647A2 (en) | 2018-12-04 |
MX2018007804A (en) | 2019-07-04 |
KR20180095051A (en) | 2018-08-24 |
IL260123A (en) | 2018-07-31 |
WO2017112815A1 (en) | 2017-06-29 |
RU2018126984A (en) | 2020-01-23 |
EP3394072A4 (en) | 2019-05-29 |
EA201891511A1 (en) | 2018-12-28 |
CA3009324A1 (en) | 2017-06-29 |
PH12018501351A1 (en) | 2019-02-27 |
EP3394072A1 (en) | 2018-10-31 |
CL2018001733A1 (en) | 2018-11-09 |
CO2018007535A2 (en) | 2018-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201805092WA (en) | Cortistatin analogs and uses thereof | |
SG11201804161VA (en) | Compositions comprising bacterial strains | |
SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
SG11201811414TA (en) | Heterocyclic compounds as immunomodulators | |
SG11201804787UA (en) | Human immunodeficiency virus neutralizing antibodies | |
SG11201806745RA (en) | Sulfonylureas and related compounds and use of same | |
SG11201804363UA (en) | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors | |
SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
SG11201804294WA (en) | Tank-binding kinase inhibitor compounds | |
SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
SG11201810579YA (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
SG11201407793TA (en) | Compounds and compositions for modulating egfr activity | |
SG11201407268SA (en) | Nuclear transport modulators and uses thereof | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201804774YA (en) | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 |